---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-068334"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2022-06-06T23:59:59+00:00"
generated_at: "2026-06-25T04:18:23.151328+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Quanterix appoints Karen A. Flynn to Board of Directors effective June 6, 2022

## Summary
- Appointed Karen A. Flynn as Class I director, term through 2024 annual meeting.
- Initial equity award valued at $400,000: 60% stock options, 40% RSUs, vesting over three years.
- Flynn is SVP and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT).
- No family relationships or arrangements with other directors/officers disclosed.

## SEC filing metadata
- accession: 0001104659-22-068334
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2022-06-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000110465922068334/0001104659-22-068334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000110465922068334/tm2217713d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-068334
- JSON: https://secwatch.observer/filing/0001104659-22-068334.json
- Plain text: https://secwatch.observer/filing/0001104659-22-068334.txt

## Key facts
- Executive change
  Karen A. Flynn was appointed as Class I Director at Quanterix Corp.
  - Action: appointed
  - Role: Class I Director
  source text: On June 3, 2022, the board of directors (the “Board”) of Quanterix Corporation (the “Company”) appointed Karen A. Flynn to serve on the Board, effective as of June 6, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000110465922068334/0001104659-22-068334-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.